Core Viewpoint - The collaboration between Insilico Medicine and Shenzhen Hengtai Biotechnology aims to accelerate the global development of ISM8969, a novel NLRP3 inhibitor for treating central nervous system diseases [1] Group 1: Partnership Details - Insilico Medicine and Hengtai Biotechnology have entered into a co-development agreement for the ISM8969 project [1] - Insilico Medicine grants Hengtai Biotechnology 50% rights for research, development, registration, production, and commercialization of ISM8969 globally [1] Group 2: Financial Aspects - Insilico Medicine is set to receive over HKD 500 million in total prepayments and milestone payments, including an initial payment of HKD 78 million expected within 30 days of the agreement's effective date [1] Group 3: Development Responsibilities - Insilico Medicine will lead the early clinical development of ISM8969, including the submission of new drug clinical trial applications and conducting Phase I clinical trials for Parkinson's disease indications [1] - Hengtai Biotechnology will take charge of subsequent global clinical research, regulatory registration, and commercialization efforts [1]
逾5亿港元合作 英矽智能与衡泰生物共同开发创新透脑性NLRP3抑制剂